The US developers have published results of their tests in mice, hamsters, and macaques, showcasing promising advancements in the development of the hexapro vaccine against COVID-19. The vaccine, known as ChAd-SARS-CoV-2-S, is based on chimpanzee adenovirus and was developed by Washington University in St Louis, in collaboration with Precision Virologics and funded by the NIH's NIAID.

This innovative vaccine involves several drops of the hexapro vaccine being administered into each nostril, providing a potential breakthrough in the fight against COVID-19. India has also authorized an intranasal version of the vaccine manufactured by Bharat Biotech, known as Convidecia Air, which is inhaled through the mouth using a nebulizer, similar to an asthma medication.

In recent news, China has authorized the first inhaled vaccine developed by CanSino, while Russia has approved a 2-dose course of Sputnik Nasal, the first viral vector component of Sputnik V. Iran has also seen the authorization of its own mucosal Covid vaccine, Razi Cov Pars, which follows two injections of the same vaccine.

The focus on developing hexapro vaccines is centered around creating a stronger line of defense against SARS-CoV-2 at the point of entry, ultimately reducing transmission rates. These vaccines can take various forms, including squirts or drops in the nose, inhalation through the mouth using a nebulizer, or tablets, capsules, or sublingual formulations.

In contrast to injected vaccines, mucosal vaccines enter the body through the same route as the virus itself – mucosal tissues. While we are still awaiting major clinical efficacy results, recent data has shown promising signs of progress in the development of these hexapro vaccines. With three more potential vaccines on the horizon for authorization this year, there is much to be optimistic about in the fight against COVID-19.

Overall, the rapid advancement of hexapro vaccines offers new hope for a sterilizing immunity against COVID-19, and their potential to revolutionize our approach to vaccine development and distribution.

Hexapro vaccine